Advertisement
Australia markets closed
  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     
  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     
  • AUD/USD

    0.6409
    -0.0016 (-0.25%)
     
  • OIL

    83.03
    +0.30 (+0.36%)
     
  • GOLD

    2,407.60
    +9.60 (+0.40%)
     
  • Bitcoin AUD

    99,495.53
    +332.77 (+0.34%)
     
  • CMC Crypto 200

    1,386.15
    +73.53 (+5.83%)
     
  • AUD/EUR

    0.6021
    -0.0010 (-0.16%)
     
  • AUD/NZD

    1.0892
    +0.0017 (+0.16%)
     
  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     
  • NASDAQ

    17,089.64
    -304.67 (-1.75%)
     
  • FTSE

    7,895.85
    +18.80 (+0.24%)
     
  • Dow Jones

    37,857.39
    +82.01 (+0.22%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

23andMe Holding Third Quarter 2024 Earnings: US$0.58 loss per share (vs US$0.20 loss in 3Q 2023)

23andMe Holding (NASDAQ:ME) Third Quarter 2024 Results

Key Financial Results

  • Revenue: US$44.7m (down 33% from 3Q 2023).

  • Net loss: US$278.0m (loss widened by 202% from 3Q 2023).

  • US$0.58 loss per share (further deteriorated from US$0.20 loss in 3Q 2023).

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

23andMe Holding Earnings Insights

Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Healthcare industry in the US.

Performance of the American Healthcare industry.

The company's shares are down 13% from a week ago.

Risk Analysis

You should learn about the 3 warning signs we've spotted with 23andMe Holding (including 1 which doesn't sit too well with us).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.